These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10654630)

  • 21. Changes in resistance to aminoglycoside antibiotics of different bacterial strains isolated during the period 1978 to 1983. Netilmicin as alternative therapy.
    Bovelacci A; Montini G; Ramacciotti PG
    Chemioterapia; 1985 Dec; 4(6):439-44. PubMed ID: 3830413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aminoglycoside resistant enterococcal endocarditis.
    Eliopoulos GM
    Infect Dis Clin North Am; 1993 Mar; 7(1):117-33. PubMed ID: 8463648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Routine cycling of antimicrobial agents as an infection-control measure.
    Fridkin SK
    Clin Infect Dis; 2003 Jun; 36(11):1438-44. PubMed ID: 12766840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Will new antimicrobials overcome resistance among Gram-negatives?
    Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The aminoglycosides. Streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, sisomicin.
    Edson RS; Keys TF
    Mayo Clin Proc; 1983 Feb; 58(2):99-102. PubMed ID: 6823164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
    Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
    J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of Enterococcus faecalis to twelve antibiotics, time-kill assays, and high-level aminoglycoside resistance in a university hospital in Argentina.
    Predari SC; Gutiérrez MA; Ribas C; Molinari GS; Santoianni JE
    Rev Argent Microbiol; 1991; 23(2):67-78. PubMed ID: 1815269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of resistance to aminoglycoside drugs in hospital strains of Staphylococcus aureus].
    Petreska-Sibinovska D; Mraović M; Dotlić R
    Srp Arh Celok Lek; 1991; 119(5-6):138-42. PubMed ID: 1792564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolution of aminoglycoside therapy: a single daily dose.
    Deamer RL; Dial LK
    Am Fam Physician; 1996 Apr; 53(5):1782-6. PubMed ID: 8623702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Replacement of gentamicin by amikacin as a means of decreasing gentamicin resistance of gram-negative rods in a neonatal intensive care unit.
    Wielunsky E; Drucker M; Cohen T; Reisner SH
    Isr J Med Sci; 1983 Nov; 19(11):1006-8. PubMed ID: 6662682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to aminoglycoside antibiotics of gram-negative bacilli isolated in Canadian hospitals.
    Duncan IB; Cheung EY; Haldane EV; Jackson FL; McNaughton RD; Morisset RA; Noble MA; Rennie RP; Ronald AR; Smith JA
    Can Med Assoc J; 1981 May; 124(9):1165-7. PubMed ID: 7237336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The aminoglycosides.
    Edson RS; Terrell CL
    Mayo Clin Proc; 1999 May; 74(5):519-28. PubMed ID: 10319086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns.
    Braveny I; Voeckl J; Machka K
    Arzneimittelforschung; 1980; 30(3):491-5. PubMed ID: 7387761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combination therapy against vancomycin-resistant enterococci].
    Kariyama R; Kumon H
    Nihon Rinsho; 2001 Apr; 59(4):733-8. PubMed ID: 11304998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups.
    Miller GH; Sabatelli FJ; Naples L; Hare RS; Shaw KJ
    J Chemother; 1995 Jun; 7 Suppl 2():31-44. PubMed ID: 8622109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro sensitivity at 18 antibiotics of 192 strains of Pseudomonas aeruginosa isolated at Garches Hospital].
    Ronco E; Vacheron F; Orabona A
    Pathol Biol (Paris); 1987 May; 35(5):558-62. PubMed ID: 3112708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The microbial genetics of antibiotic cycling.
    John JF; Rice LB
    Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S22-31. PubMed ID: 10654632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aminoglycoside adaptive resistance: importance for effective dosage regimens.
    Barclay ML; Begg EJ
    Drugs; 2001; 61(6):713-21. PubMed ID: 11398904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial cycling: the future or a fad?
    Hodges BM; White RL
    Ann Pharmacother; 2001 Oct; 35(10):1224-32. PubMed ID: 11675852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.